Trials / Withdrawn
WithdrawnNCT04482842
Gene-guided Warfarin for Anticoagulation Therapy
Gene-guided Warfarin for Anticoagulation Therapy in Patients With Acute Ischemic Stroke
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study will explore the effect of warfarin gene polymorphism on the effectiveness and safety of anticoagulant therapy in patients with acute ischemic stroke, and clarify the correlation between genetic testing and compliance rate of INR value. It will illustrate the significance of gene-guided warfarin for administered dose to anticoagulation therapy in patients with acute ischemic stroke. Then it will establish and verify a warfarin stable dose prediction model suitable for such patients, and provide basis for the personalized medication regimen of warfarin in patients with acute ischemic stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Gene detection (CYP2C9*3, VKORC1) | Warfarin is administered at the recommended dose by detecting CYP2C9\*3 and VKORC1 gene polymorphismsand. The doctor adjusts the dosage according to the fluctuation of INR value in time. |
| DRUG | Warfarin Sodium | Warfarin is administered at a gene-guided dose or at a regular dose. |
Timeline
- Start date
- 2020-12-10
- Primary completion
- 2021-08-20
- Completion
- 2021-08-20
- First posted
- 2020-07-23
- Last updated
- 2021-08-25
Source: ClinicalTrials.gov record NCT04482842. Inclusion in this directory is not an endorsement.